United Therapeutics Corporation (NASDAQ:UTHR) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.

On March 12, 2026, Cantor Fitzgerald raised its price target on United Therapeutics Corporation (NASDAQ:UTHR) from $525 to $625 and maintained an Overweight rating on the stock. According to the analyst, the idiopathic pulmonary fibrosis remains the company’s top investment catalyst. The firm noted that if the TETON-1 clinical trial delivers expected results, the stock will see significant upside, with its per-share value reaching over $600 in the coming months. It will also strengthen the company’s leadership in treating this critical lung condition.

Separately, on March 9, 2026, United Therapeutics Corporation (NASDAQ:UTHR) authorized a new $2 billion stock repurchase program. The company launched an initial $1.5 billion accelerated share repurchase (ASR) via agreements with Citibank. This includes both collared and uncollared structures. As part of the agreement, the company made an upfront payment on March 11, which was immediately followed by the delivery of approximately 50% to 70% of the anticipated shares under the collared and uncollared ASR agreement. The remaining $500 million remains available for discretionary buybacks over a 1-year period.

Founded in 1996, United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on rare lung diseases. Headquartered in Silver Spring, Maryland, the company develops pharmaceuticals and technologies related to organ transplantation.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.